株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

閉経後骨粗鬆症の世界市場の分析と予測

Global Postmenopausal Osteoporosis Market Research and Forecast 2018-2023

発行 Orion Market Research Pvt Ltd 商品コード 701134
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.77円で換算しております。
閉経後骨粗鬆症の世界市場の分析と予測 Global Postmenopausal Osteoporosis Market Research and Forecast 2018-2023
出版日: 2018年08月03日 ページ情報: 英文
概要

当レポートでは、世界の閉経後骨粗鬆症の治療薬の市場について分析し、疾患の概要や市場の基本構造、外部からのマクロ的・ミクロ的影響、主な促進・抑制要因、治療薬の種類別・流通チャネル別・地域別の市場動向の見通し (今後7年間分)、最新の市場競争状況、主要企業のプロファイルなどを調査しております。

第1章 分析概要

第2章 市場の概略と考察

  • 定義
  • アナリストの見解と現在の市場動向
    • 分析のポイント
    • 提言
    • 結論
  • 世界各国の規制状況 (米国、欧州、中国、インドなど)

第3章 市場の決定要因

  • 促進要因
  • 抑制要因
  • 市場機会

第4章 市場区分

  • 治療薬別
    • ビスホスホネート
    • ホルモン
    • ラネリック酸ストロンチウム
    • ラロキシフェン
    • デノスマブ
  • 流通チャネル別
    • 院内薬局
    • 小売薬局
    • オンライン薬局 (eコマース)

第5章 競争環境

  • 主要戦略の分析
  • 主要企業の分析

第6章 地域別分析

  • 北米市場 (米国、カナダなど)
  • 欧州市場 (英国、フランス、ドイツ、イタリア、スペインなど)
  • アジア太平洋地域市場 (インド、中国、日本)
  • 他の国々 (RoW) の市場

第7章 企業プロファイル

  • ALLERGAN PLC
  • AMGEN INC.
  • BIOLOGICSMD, INC.
  • DELTANOID PHARMACEUTICALS, INC.
  • ELI LILLY AND COMPANY
  • ENTERIS BIOPHARMA, INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • GLAXOSMITHKLINE PLC
  • LIGAND PHARMACEUTICALS, INC.
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • NOVEN PHARMACEUTICALS, INC.
  • NOVO NORDISK A/S
  • ONCOBIOLOGICS INC.
  • PARAS BIOPHARMACEUTICALS FINLAND OY
  • PFIZER INC.
  • PHYTOHEALTH CORPORATION
  • PROCTER & GAMBLE CO.
  • RADIUS HEALTH INC.
  • SANOFI S.A.
  • TARSA THERAPEUTICS, INC.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD
図表

List of Tables

  • TABLE # 1 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL BISPHOSPHONATES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL HORMONES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL STRONTIUM RANELATE RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL RALOXIFENE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL DENOSUMAB MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL E- COMMERCE PHARMACIES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
  • TABLE # 11 NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 12 NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
  • TABLE # 13 NORTH AMERICAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)
  • TABLE # 14 EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 15 EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
  • TABLE # 16 EUROPEAN POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)
  • TABLE # 17 ASIA PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 18 ASIA PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
  • TABLE # 19 ASIA PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)
  • TABLE # 20 REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
  • TABLE # 21 REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY TREATMENT, 2017 VS 2023 (IN %)
  • FIGURE # 2 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY DISTRIBUTION CHANNEL, 2017 VS 2023 (IN %)
  • FIGURE # 3 US POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 4 CANADA POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 5 UK POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 6 FRANCE POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 7 GERMANY POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 8 ITALY POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 9 SPAIN POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 10 ROE POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 11 INDIA POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 12 CHINA POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 13 JAPAN POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 14 ROASIA PACIFIC POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
  • FIGURE # 15 REST OF THE WORLD POSTMENOPAUSAL OSTEOPOROSIS MARKET SIZE, 2017-2023 ($MILLION)
目次
Product Code: OMR2018364

The postmenopausal osteoporosis market is expected to grow significantly during the forecast period (2018-2023). Osteoporosis is a skeletal disorder characterized by skeletal fragility, microarchitectural disruption, and low bone mass. It is a condition where the bone density and bone mass decreases and in the long run increases the risk of bone fracture. The global postmenopausal osteoporosis market is significantly growing due to some factors which include increasing geriatric population. Age is the major factor for the cause of the osteoporosis disease, hence rising geriatric population contributes in the market growth. Factors such as growing prevalence of osteoporosis and developing healthcare infrastructure across the globe also drive the growth of the segment.

Changing lifestyle of people due to consumption of alcohol and smoking, mounting awareness among people through awareness initiatives and programs and continuous innovations in the drugs with the approval by the FDA creates the future opportunity for the growth of the market. On the other hand, there are various factors acting as the barriers for the market which includes the requirement of high standards for the approval of new product launch and increasing competition from the generics.

Global postmenopausal osteoporosis market can be segmented on the basis of treatment and distribution channel. Based on the treatment, the market can be further diversified as bisphosphonates, hormones, strontium ranelate, raloxifene and denosumab. Among the treatment, bisphosphonates segment is expected to lead the market as it is extensively used for the prevention and treatment of postmenopausal osteoporosis. Furthermore, on the basis of distribution channel, the market can be bifurcated as hospital pharmacies, retail pharmacies and E-commerce pharmacies.

Considering the geographical regions, the global Postmenopausal Osteoporosis market is divided into North America, Europe, Asia Pacific, and Rest of the world. The largest market share is covered by North America due to growing geriatric population, high level of developed technologies and healthcare spending. Europe is the region which covers significant market share due to increase in research and development and new product innovations. Asia Pacific considered as the fastest growing economy with the rising awareness among people, developing technologies and healthcare infrastructure.

The companies contributing to the global market includes Eli Lilly and company, Pfizer Inc., Proctor & Gamble Co., Amgen Inc., Novartis International AG, Allergan plc, Deltanoid Pharmaceuticals Inc., Novo- Nordisk A/S, and Phytohealth Corporation. The companies are entering into mergers and partnership in order to introduced new product innovation which in return enhance the market growth. For an instance: Radius Health, Inc. in April 2017, received FDA approval for TYMLOS (abaloparatide) injection to treat postmenopausal women with osteoporosis. TYMLOS in postmenopausal women with osteoporosis, reduce the risk of vertebral and nonvertebral fractures.

Research methodology

The market study of Postmenopausal osteoporosis market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Authentic Public Databases such as International Osteoporosis Foundation, National Institute of Health, Agency for Clinical Innovation, National Osteoporosis Foundation and others.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalogue
  • Supplier Websites such as Alibaba, amazon for pricing analysis

The report is intended for osteoporosis drug manufacturers, healthcare provider, research and development companies, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers and initial norms.

Market segmentation

Global Postmenopausal osteoporosis market is segmented on the basis of regional outlook and following segments:

  • 1. Global Postmenopausal osteoporosis market Research and Analysis, By Treatment
  • 2. Global Postmenopausal osteoporosis market Research and Analysis, By Distribution Channel
  • 3. Global Postmenopausal osteoporosis market Research and Analysis, By Region

THE REPORT COVERS:

  • Comprehensive research methodology of global Postmenopausal osteoporosis market.
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Postmenopausal osteoporosis market.
  • Insights about market determinants which are stimulating the global Postmenopausal osteoporosis market.

Table of Contents

1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS &CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
    • 2.3.1. UNITED STATES
    • 2.3.2. EUROPEAN UNION
    • 2.3.3. CHINA
    • 2.3.4. INDIA
    • 2.3.5. REST OF THE WORLD

3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. INCREASING PREVALENCE OF OSTEOPOROSIS
    • 3.1.2. EARLY ONSET OF MENOPAUSE DUE TO LIFESTYLE CHANGES
    • 3.1.3. NOVEL THERAPIES SUCH AS CATHEPSIN K INHIBITOR FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
  • 3.2. RESTRAINTS
    • 3.2.1. SLOW PROCESS OF APPROVAL OF NEW PRODUCTS
    • 3.2.2. COMPETITION FROM GENERICS
  • 3.3. OPPORTUNITIES
    • 3.3.1. INNOVATIONS IN THE OSTEOPOROSIS DRUGS AND ROBUST PIPELINE
    • 3.3.2. AWARENESS PROGRAMS AND INITIATIVES TO FUEL THE MARKET
    • 3.3.3. COMPANIES COLLABORATING TO IMPROVE TREATMENT

4. MARKET SEGMENTATION

  • 4.1. BY TREATMENT
    • 4.1.1. BISPHOSPHONATES
    • 4.1.2. HORMONES
    • 4.1.3. STRONTIUM RANELATE
    • 4.1.4. RALOXIFENE
    • 4.1.5. DENOSUMAB
  • 4.2. BY DISTRIBUTION CHANNEL
    • 4.2.1. HOSPITAL PHARMACIES
    • 4.2.2. RETAIL PHARMACIES
    • 4.2.3. E- COMMERCE PHARMACIES

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY MARKET STRATEGIES
  • 5.2. KEY COMPANY ANALYSIS

6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
    • 6.1.3. REST OF NORTH AMERICA
  • 6.2. EUROPE
    • 6.2.1. UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. SPAIN
    • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
  • 6.4. REST OF THE WORLD

7. COMPANY PROFILES

  • 7.1. ALLERGAN PLC
  • 7.2. AMGEN INC.
  • 7.3. BIOLOGICSMD, INC.
  • 7.4. DELTANOID PHARMACEUTICALS, INC.
  • 7.5. ELI LILLY AND COMPANY
  • 7.6. ENTERIS BIOPHARMA, INC.
  • 7.7. F. HOFFMANN-LA ROCHE LTD.
  • 7.8. GLAXOSMITHKLINE PLC
  • 7.9. LIGAND PHARMACEUTICALS, INC.
  • 7.10. MERCK & CO., INC.
  • 7.11. NOVARTIS INTERNATIONAL AG
  • 7.12. NOVEN PHARMACEUTICALS, INC.
  • 7.13. NOVO NORDISK A/S
  • 7.14. ONCOBIOLOGICS INC.
  • 7.15. PARAS BIOPHARMACEUTICALS FINLAND OY
  • 7.16. PFIZER INC.
  • 7.17. PHYTOHEALTH CORPORATION
  • 7.18. PROCTER & GAMBLE CO.
  • 7.19. RADIUS HEALTH INC.
  • 7.20. SANOFI S.A.
  • 7.21. TARSA THERAPEUTICS, INC.
  • 7.22. TEVA PHARMACEUTICALS INDUSTRIES LTD